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Abstract
Alzheimer’s disease is currently a health care problem and in the future, when 
we have effective treatments, it will become a public health priority. Health sys-
tems should adapt to this situation. New technologies are tools that can improve 
healthcare and lower costs. The mobile phone with call o video call conference is 
going to suppose a radical change in the control of these patients. The telephone 
assistance to patient or relatives is very satisfactory for both due to the rapidity in 
the response to their problem and the comfort with which they are attended to. 
Also the health system reduces the costs of face-to-face consultation.  
In addition, this telemedicine could be applied for cognitive stimulation, with 
specific programs for each patient and for the follow-up of patients in their 
homes, delaying their entry into residences. The objective is to turn the patients 
and their caregiver into cotherapists together with the nurse and the physician, 
in the follow-up of Alzheimer’s disease.
Keywords: healthcare, Alzheimer’s disease
1. Alzheimer’s disease: public health priority
Alzheimer’s disease (AD) is a degenerative disease produced by the accumula-
tion of beta-amyloid and tau protein in the brain. From the clinical point of view, 
it is characterized by a prodromal phase with mild cognitive impairment, which is 
followed by the dementia phase [1].
Early dementia screening by a primary care physician should be completed 
once a patient or a knowledgeable informant has noticed decline in memory or 
difficulty [2]. Screening is not indicated at the general population level [3, 4], 
because currently there are no specific treatments to block the progression of 
cognitive decline in AD and other neurocognitive dementias. Is very important 
reasons from a patient’s social and personal perspective that an early diagnosis 
is important as Alzheimer’s disease is a terminal illness; you can minimize some 
of the effects if you understand the disease and know what to do [5]. Numerous 
screening tests are available for confirmed cognitive impairment, and laboratory 
tests and imaging studies should be obtained to rule out reversible etiologies. If 
patients meet diagnostic criteria for AD, clinicians should educate patients and 
caregivers on the expected course and help them complete advance directives. 
Troublesome behaviors should be managed with nonpharmacotherapeutic mea-
sures first. Drugs for improving cognition can be prescribed but do not prevent 
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disease progression [6]. Patients with advanced illness need end of life care 
(EoLC) with adequate pain control and palliative care interventions to shorten 
their hospital stay. Bamford et al. [7] take seven factors influencing good EoLC for 
people with dementia (Table 1). By incorporating stakeholders’ perspectives and 
preferences when planning and developing coordinating interventions, we may 
increase the likelihood of successful implementation and patient benefits [8].
In 1984, the National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRA) developed the first diagnostic criteria for Alzheimer’s dementia 
[9]. In 2011, the National Institute of Aging/Alzheimer’s Association (NIA-AA) 
revised these criteria including two new phases of the disease and introduced the 
utilization of biomarkers in research. Firstly, the introduction of the use  
of biomarkers would aim to detect pathological changes of AD before the onset of 
cognitive symptoms—“the preclinical phase” [10]. Secondly, the introduction of  
a mildly symptomatic but not dementia phase, which defines the onset of mild cog-
nitive symptoms, was introduced. Clinical biomarkers such as deposition of Aβ seen 
on PET imaging were introduced to increase the clinical likelihood of diagnosis of 
AD on the presentation of mild cognitive impairment (MCI) however, these are yet 
to be utilized for routine clinical use [11]. In 2014, the International Working Group 
updated their clinical entity of prodromal AD by introducing improved biomarkers 
for AD and defining a criteria for atypical and non-AD dementia [12]. And finally, 
the diagnostic standard for dementia is the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5). DSM-5 recognizes two cognitive syn-
dromes: major neurocognitive impairment and mild neurocognitive impairment. 
The diagnosis of major neurocognitive impairment requires objective cognitive 
Table 1. 
Summary of the seven factors influencing good EoLC for people with dementia.
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decline that is severe enough to interfere with activities of daily living and is not 
caused by delirium or another neurologic, medical, or psychiatric disorder [13].
The socio-health needs of dementias are similar, regardless of their etiology, 
although there are some peculiarities that characterize each of them like hal-
lucinations in dementia by Lewy bodies, behavioral problems in frontotemporal 
dementia, and social and emotional level of loneliness, which is higher in Korsakoff 
syndrome [14]. This social and emotional loneliness is more frequent and earlier 
income in a residence of the patients with Korsakoff syndrome [15].
In 2010, annual healthcare costs attributable to dementia were between $41,000 
and $56,000 per person [16]. About three quarters of these costs are from institu-
tional and home-based long-term care. Although these estimates place a monetary 
value on informal care provided by family members and friends, they do not 
account for the substantial non-monetary costs to caregivers in terms of negative 
consequences to social, physical, and psychological well-being [17]. If we can delay 
dependency and institutionalization, by even a couple of years, it has the potential 
to save hundreds of billions in direct healthcare costs and even more in terms of 
improved well-being for caregivers.
The AD from the clinical point of view is today a public health problem rec-
ognized by the WHO [18], because it is a very frequent disease. It is estimated 
that 46.8 million people live with dementia in the world in 2015. This number is 
expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million 
in 2050. This translates to approximately two new cases per 1000 people age 65–74, 
13 new cases per 1000 people age 75–84, and 39 new cases per 1000 people age 
85 and older, and the greatest risk factor by far is aging [19–21]. It is also a disease 
with great impact on the health of the patient, who becomes totally dependent, 
and the family environment, for their involvement in the care from the physical 
and psychological point of view. On average, a person with Alzheimer’s disease will 
spend more years (40% of the total number of years with Alzheimer’s) in the most 
severe stage of the disease than in any other stages. However, currently, and from an 
epidemiological point of view, it is not a priority in health, given that although we 
have a screening test for the population, we do not have a drug with the potential to 
significantly modify the natural course of the disease. The quality of care received 
by a person with dementia positively is critical to the physical and mental health of 
the person with dementia [22]. It is a challenge for socio-health systems to deter-
mine what needs should be provided and financed.
2. Needs and demands socio-health of the patients
Dementia is a chronic and progressive disease, with an average survival of more 
than 10 years. Patient and the family environment with this disease go through 
different phases that have different needs and demands. The needs are determined 
by the interventions that have shown efficacy through scientific studies, while 
the demands are determined mainly by sociocultural factors. A clear example of 
this is that new generations accept new technologies much better than previous 
generations [23]. Any socio-health system should try to provide its patients and 
caregivers with those needs and demands as efficiently as possible (actions with 
studies that demonstrate their effectiveness and that are viable from the economic 
point of view). In general, caregivers claim and request less formal attention than 
in other pathologies [24]. Each patient with dementia and its family have different 
characteristics and needs that require individual attention [25]. The NICE guide 
recommends periodic evaluation and caregiver programs, including telephone or 
Internet support. Such supportive interventions could be effective both preventive 
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and therapeutic of the consequences of the burden [26]. The unmet needs may 
be higher in caregivers with lower education and individuals with early-stage 
dementia and low-income. The identifying and treating symptoms of depression in 
patients with dementia and caregivers are necessary for them to know their other 
unmet needs [27].
Socio-sanitary assistance to dementia has the highest degree of complexity, 
comparable to multi-pathological patients, according to the categorization of chronic 
patients adopted by the Department of Health of the United Kingdom, the approach 
of the Kaiser Permanente. These patients require a comprehensive and continuous 
treatment, which must be based on the coordination of healthcare and social assis-
tance, as well as between the different levels of care (primary care and specialized 
care). And more specifically in health care, the link between the specialist physician 
and the case management nurse of the unit with primary care is key, so that this 
assistance has a versatility that allows ensuring adequate care more appropriate [28].
The personalized care plan focuses on the patient with the disease but involves 
the entire family environment of the patient, understanding this environment 
widely, including friends and volunteers, among others.
The aim of the personalized care plan are: (1) promotion of the autonomy of 
the patient with activation and self-management of care and improvement of their 
quality of life; (2) pharmacotherapeutic optimization at all times during the disease; 
(3) prevent complications, cognitive and functional impairment, and ultimately 
dependence; (4) integral assessment of the patient from a biomedical or clinical, 
psychological, functional and socio-family point of view; (5) establishment of a 
prognosis in each phase of the disease; (6) establish advance planning of decisions.
The needs or demands of patients and caregivers with dementia are typified 
and all socio-health systems establish different socio-sanitary responses to similar 
pathologies [26, 29, 30]. However, this assistance must be individualized in each 
specific user always, considering it as a biopsychosocial organism, with its particular 
desires and preferences. Therefore, assistance to users with AD must be protocolized 
in a multidisciplinary way and provided individually to each patient and caregiver.
In spite of the increase of the income in residences in the last years, the family 
environment is the therapeutic reference that is more effective, efficient, and very 
difficult to substitute for the emotional implications that it has. And above all, it is 
preferred by most patients with dementia [31–33]. The competence of caregivers is 
essential for the life quality of patient with dementia, and multicomponent inter-
ventions may be appropriate for nurses to practice [34].
3. Social sanitary assistance management tools
We must overcome health care in the terms of first-visit patients and regulated 
reviews (at 3, 6, 9, or 12 months) and use management tools that use information 
and communication technologies to satisfy the needs and demands, avoiding refer-
rals, appointments, and bureaucratic reviews.
Among the emerging management tools in recent years that are most useful are:
1. Caregivers: we have to pay much more attention to the caregiver or caregivers 
and use them as cotherapists, throughout the process, especially in the final 
phase [35].
2. Case management nurse [36, 37]: together with the medical specialist or gen-
eral practitioner who is, usually, the axis around which health care is provided. 
The case management nurse coordinates all the actions of the patient and their 
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family. The liaison nurse of the dementia unit, within a neurology service, was 
the axis around which social-health assistance was established. In our study 
[37], the case management nurse of the dementia unit, was the axis around 
which social-health assistance was established.
3. Coordination with de Alzheimer’s association using their ability to bring 
together the patient and the family environment, using their infrastructures 
and volunteering to monitor users [38, 39].
4. Digital clinical history: access to the digital clinical history instantly, from any 
terminal of the health system (both primary care and specialized care), allows to 
efficiently solve healthcare problems in relation to the patient without the incon-
venience of having to travel or the delay of having to wait for an appointment.
5. Prescription on line: also accessible from any terminal of the health system. It 
allows to see the medication prescribed by any doctor to the patient. It has the 
potential to establish alerts, system of interactions and allergies, and maxi-
mum duration of treatments, among others.
6. Telecare: At the beginning it arose to solve the problems of accessibility in 
remote areas and sanitary underfunded, allowed accessibility by spacing dis-
tances. Subsequently, it was considered that telemedicine contributed essential 
quality by facilitating the continuity of care, and recently it is considered an 
efficient and essential tool in the organization of health care. The application 
of technology in health has become a strategic objective to address the demo-
graphic challenge and allow “aging at home.”
The modalities of telecare can be very diverse, and the telemedicine projects of 
attention to users with dementia performed include [1] support for patients so that 
they can continue to live independently; [2] support services for informal caregivers 
through “online” training, video conferencing with professionals, telealarm with 
videoconference, and cognitive stimulation; [3] networks for patient and caregiv-
ers; [4] monitoring of the state of the patient, personalized intervention, and adap-
tive care; [5] platform that integrates smart home technologies, with sensors and 
interoperability with professionals and institutions; and [6] computer programs to 
caregivers to improve their overload, mainly emotional.
The main problems of this technology are the risks of privacy in relation to data 
protection and health care. Other issues technological aspects that are solved with the 
progress of technology: complexity of use, cost of acquisition and technical failures.
The main resistance for its establishment is given by the three protagonists of the 
assistance: patients and caregivers, professionals, and mainly the managers of the 
health administration [40].
These tools used by each socio-health system according to their possibilities 
allow a better assistance to patients and caregivers.
4. Health model units of cognitive disorder and conduct
Dementia is the paradigm of disease that practically in its entirety is diagnosed 
and/or followed by the national health systems (public and free). It is a disease that 
does not start abruptly and for which medicines are expensive. Patient assistance 
involves the neurologists and other specialists who directly assist patients with neuro-
logical problems. The growing complexity of neurology in general, as a specialty, with 
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the improvement of diagnostic methods as well as therapeutic interventions, means 
that the assistance provided by a neurologist or psychiatrist or geriatrist is greater.
The guiding principles of the assistance in the unit of memory are [1] univer-
sality and equality; [2] integrality and transversality, with coordination of all the 
members; and [3] efficiency and sustainability. This unit must be endowed with the 
human and material resources to meet its objectives [41, 42].
• Comprehensive care for affected people and support for caregivers in all phases 
of dementia.
• Information, training, and advice to affected people, caregivers, associations, 
and professionals involved in dementia assistance.
• Sensitization of public opinion, institutions, entities, and media.
• Adequacy of health and social resources, as well as the establishment of proto-
cols and joint procedures.
• Promotion of volunteering and promotion of associations.
• Promote lines of research and intervention.
To fulfill these objectives, within the unit there should be another specialist 
doctor (neurologist, psychiatrist, and geriatrist), nurse manager of hospital cases, 
clinical psychologist or neuropsychologist, and social worker.
In primary care, it should consist of a family doctor and nurse who manages 
primary care cases and social work. The coordination and communication between 
these professionals is key in dementia care process.
To carry out all its objectives, you should use the tools, mainly new technologies, of 
which the health system has: digital clinical history, prescription “online,” and telecare.
Key aspects in the operation of the unit that should be considered:
1. Management of communication at all levels: horizontal internal, between the 
members of the unit among themselves and with the other professionals of the 
organization; internal vertical, with the address of the hospital and primary 
care center; external with patients and relatives, with associations of relatives 
of patients and with society in general [43].
2. Control of the satisfaction of all those who participate in the unit: patients 
and relatives, professionals, and the administration in relation to the activities 
developed in relation to the healthcare process.
3. Establish indicators of care process, health outcomes, and specific situations: 
all this must be reflected in an annual report of the unit, which includes all the 
activity of the unit carried out, mainly in the care, research, and teaching areas.
The personalized attention in the chronic disease improves the indicators of 
physical and psychological health, as well as the ability to manage the disease with 
respect to usual care. The differences increase when they are more complete and more 
intense and integrated into the routine. Care with a more personalized and gradu-
ated approach allows to maintain the autonomy and integration of the patient in his 
environment [44, 45]. The coordination at the health level between primary and 
specialized care, with a social worker and in association with Alzheimer’s patients’ 
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relatives, all tools being available (telephone, email, digital medical record, prescrip-
tion “online”), is key for the success in monitoring patients and caregivers [37].
5. Future perspectives
The optimism generated by recent and anticipated developments in the under-
standing and treatment of Alzheimer’s disease presents a great opportunity to innovate 
and adapt our services to incorporate the next exciting development in the field of 
dementia [46]. Almost 100 treatments are currently being investigated, often target-
ing individuals earlier in the disease process, and a very promising phase II work has 
been published about the antibody aducanumab [47]. Today, health services in Europe 
would not be prepared to treat patients with Alzheimer’s disease that are subsidized 
by an effective treatment [48]. It seems likely that interventions will be available in the 
near future for people diagnosed with prodromal dementia. This would fundamentally 
transform how the Alzheimer’s disease is perceived, diagnosed, and managed.
There are two key points: [1] equity in access of patients and caregivers and [2] 
specific preparation of professionals. There will be a need for substantial education 
and training for primary and secondary care professionals about new disease-
modifying treatment for Alzheimer’s disease. In primary care this would need to 
focus on early symptoms and risk factors. In secondary care it would cover the safe 
and effective use of biomarkers. A reconfigured service would require seamless 
collaboration between disciplines, patient groups, and specialties in order to expand 
the dementia-focused clinical services to include an Alzheimer’s disease service. 
While many people currently present with moderate or severe dementia, in the 
future, hopefully the majority of people will be diagnosed much earlier, even in the 
prodromal/preclinical stages. A distinct approach for the preclinical, prodromal, 
and dementia stages of Alzheimer’s disease would be necessary.
• Healthcare systems will need to identify and engage with prodromal popula-
tions who might benefit from such interventions. These people may not 
be in contact with health services or, if they are, this will not be because of 
Alzheimer’s disease.
• Realistic planning is needed now to direct the evolution of services to optimize 
appropriate patient access and prepare protocols for phase IV testing of these 
treatments to inform real-world practice and commissioning decisions.
Although in the near future we will have treatment for Alzheimer’s disease, the 
social-health system will have to continue providing assistance in stages of dementia, 
in an integral and personalized way, adapting to the specific needs of each case that 
is determined by the type of dementia (frontotemporal, dementia by bodies of Lewy, 
and Korsakoff syndrome), characteristics of the patient, or caregiver environment.
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